EurekaMag.com logo
+ Site Statistics
References:
54,215,046
Abstracts:
30,230,908
PMIDs:
28,215,208
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Pseudogout associated with the use of cyclical etidronate therapy



Pseudogout associated with the use of cyclical etidronate therapy



Scottish Medical Journal 36(2): 49



Recently the use of etidronate in a cyclical fashion has been shown to be of value in the treatment of osteoporosis. Like all bisphosphonates etidronate is structurally similar to pyrophosphate, further it is also known to interfere with phosphate handling by the kidney resulting in elevated plasma phosphate levels. This report describes the case of a patient with established osteoporosis who developed pseudogout associated with cyclical etidronate use. The possible mechanism responsible for this is discussed.

(PDF emailed within 1 workday: $29.90)

Accession: 033019961

Download citation: RISBibTeXText

PMID: 1906636



Related references

The effects of adfr coherence therapy with phosphorus and etidronate or cyclical therapy with etidronate alone in treatment of postmenopausal osteoporosis. European Journal of Clinical Investigation 19(2 PART 2): A88, 1989

Effects of cyclical etidronate combined with calcitriol versus cyclical etidronate alone on spine and femoral neck bone mineral density in postmenopausal osteoporotic women. Annals of the Rheumatic Diseases 57(6): 346-349, 1998

The increased effect of combined cyclical etidronate and estrogen compared to etidronate alone is not dependent of the duration of estrogen use prior to starting etidronate. Journal of Bone & Mineral Research 14(SUPPL 1): S404, Sept, 1999

Pseudogout attack induced during etidronate disodium therapy. Modern Rheumatology 16(2): 117-119, 2006

Cyclical etidronate therapy and postgastrectomy osteoporosis. British Journal of Surgery 81(8): 1168-1169, 1994

Effects of cyclical etidronate therapy on bone loss in early postmenopausal women who are not undergoing hormonal replacement therapy. Osteoporosis International 7(3): 213-218, 1997

The effectiveness of cyclical etidronate therapy A long term study. Arthritis & Rheumatism 42(9 SUPPL ): S290, Sept, 1999

Longterm intermittent cyclical etidronate therapy for postmenopausal osteoporosis. Calcified Tissue International 56(5): 493, 1995

Long-term efficacy of cyclical etidronate therapy in postmenopausal osteoporosis. Irish Journal of Medical Science 166(4): 257-259, 1997

Intermittent cyclical therapy with etidronate in the prevention of corticosteroid-induced osteoporosis. Arthritis & Rheumatism 40(9 SUPPL ): S327, Sept, 1997

Intermittent cyclical etidronate therapy in the prevention and treatment of corticosteroid-induced osteoporosis. Arthritis & Rheumatism 40(9 SUPPL ): S135, Sept, 1997

Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal osteoporosis. Clinical Calcium 12(7): 937-943, 2005

Effect of cyclical etidronate and testosterone therapy on bone mineral density in men with osteoporosis. Arthritis & Rheumatism 42(9 SUPPL ): S288, Sept, 1999

A 5 year prospective study of the effect of intermittent cyclical etidronate therapy on BMD at hip and spine. British Journal of Rheumatology 36(SUPPL 1): 70, 1997

Combination of intermittent cyclical etidronate and hormone replacement therapy for postmenopausal non-responders to estrogen. Clinical Drug Investigation 22(2): 111-117, 2002